Immunization

Moderna announced interim analysis results of its investigational COVID-19 vaccine candidate, mRNA-1273, from an ongoing phase 1 study.

Here's this week's roundup of the coronavirus-related news you should know.

A collaboration between APhA and PTCB will help provide pharmacy technician credentialing in immunization delivery.

In a new guidance, the FDA provides recommendations for those developing COVID-19 vaccines to ensure safety and efficacy.

Vaccine candidates for COVID-19 are going through clinical trials at a faster rate than for any other disease.

Check out this week's most important coronavirus-related news.

Existing surveillance networks can track influenza-like illness and lead to improved assessments on impact, prevalence, and severity of COVID-19.

The MMR vaccine may demonstrate some degree of protection against septic inflammation, a symptom of COVID-19, according to a team of experts.

Researchers have discovered a new type of vaccination, which has been tested in monkeys, that could improve and sustain protection against HIV.

Keeping ahead of flu season and preventing illness through immunizations is critical to reducing an already-strained health care system.

New legislation authorizes licensed New York pharmacists to administer a vaccine for coronavirus disease 2019 (COVID-19) when it becomes available.

The CDC released an updated vaccination guidance on administering routine vaccinations amid the coronavirus disease 2019 (COVID-19) pandemic.

Pharmacies are preparing for what is expected to be a surge in flu vaccinations this year as Americans are putting a greater focus on staying healthy amid the coronavirus pandemic.

Though the COVID-19 pandemic has created intense need for treatment, rapid development of a vaccine could come at a cost.

“As pharmacists, we must continue to recommend vaccinations to all our patients.”

Pharmacies and pharmacists can help the rapid deployment of COVID-19 vaccines when available, NACDS said. 

AstraZeneca has received funds exceeding $1 billion from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production, and delivery of the University of Oxford’s coronavirus disease 2019 (COVID-19) vaccine candidate.

Moderna’s coronavirus disease 2019 vaccine candidate, mRNA-1273, showed promise in interim data from its phase 1 study.

Investigators are looking for a new way to improve upon a 100-year-old vaccine.

Investigators are developing a new needle-less vaccine delivery method that would eliminate the need for refrigeration and could significantly reduce costs associated with immunizations.

Never before have so many brilliant minds, machines, and groups come together so quickly in an attempt to develop a vaccine.

The quadrivalent meningococcal vaccine is indicated persons 2 years of age and older in the United States.

Early treatment of shingles reduces symptoms and risk of serious complications.

Pharmacist reminders boost shingles vaccination compliance.

GlaxoSmithKline and Sanofi have prioritized public health over competition in their agreement, announced today.